Condition 1: Heart Valve Replacement. Condition 2: atrial fibrillation. Presence of other heart-valve replacement Atrial fibrillation and flutter
Conditions
Interventions
Intervention group: Participants in this group receive 1000 mg of oral resveratrol daily (as four 250 mg capsules). The capsules are supplied by a reputable pharmaceutical company (Raha Pharmaceutical
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
75 Years to 18 Years
Inclusion criteria
Inclusion criteria: Obtaining informed consent from patients Patients who are candidates for valve replacement surgery Age over 18 years and under 70 years Patients are standardized in terms of their use of anti-ischemic medications including ARB/ACEI, beta-blockers, statins, and aspirin.
Exclusion criteria
Exclusion criteria: Stage 4 heart failure according to the New York Heart Association index eGFR AST, ALT Very thin people (2m/kg = 18 BMI (and very obese (2m/kg > 40 BMI) Pregnancy or suspected pregnancy Having a pacemaker (other than an epicardial pacemaker) Having or having a history of AF rhythm at the beginning Increased LA size History of any cardiac surgery in the last 6 months History of taking class III, I antiarrhythmic drugs TSH less than 0.1 Participation in other interventional clinical studies Any history of surgery Previous valve replacement and patients undergoing other surgeries at the same time, including patients with valve replacement and simultaneous CABG or redo patients No consumption of resveratrol-rich beverages and other antioxidant drugs (such as vitamin C and vitamin E, etc.) within 48 hours prior to study entry. Patients with a history of genetic coagulation disorders. Patients with thrombocytopenia (platelets below 150,000). Patients treated with dietary supplements with antiplatelet effects (such as high-dose omega-3 fish oil, garlic, ginkgo biloba, vitamin E). Patients with BLED-HAS greater than 4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative atrial fibrillation (POAF). Timepoint: within the first 72 hours after cardiac valve replacement surgery. any episode of atrial fibrillation lasting =30 seconds. Method of measurement: by continuous telemetry monitoring or 12-lead ECG. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza zibandeh gorji
Tehran University of Medical Sciences
Outcome results
None listed